"The U.S. Food and Drug Administration today approved a new use for Avastin (bevacizumab) to treat patients with persistent, recurrent or late-stage (metastatic) cervical cancer.
Cervical cancer grows in the tissues of the lower part of the "...
GYNAZOLE•1® (butoconazole nitrate) vaginal cream, 2% is indicated for the local treatment of vulvovaginal candidiasis (infections caused by Candida). The diagnosis should be confirmed by KOH smears and/or cultures (see Clinical Studies).
Note: GYNAZOLE•1® (butoconazole) is safe and effective in non-pregnant women; however, the safety and effectiveness of this product in pregnant women has not been established. (See PRECAUTIONS: Pregnancy.)
DOSAGE AND ADMINISTRATION
The recommended dose of GYNAZOLE (butoconazole) •1® is one applicatorful of cream (approximately 5 grams of the cream) intravaginally. This amount of cream contains approximately 100 mg of butoconazole nitrate.
GYNAZOLE•1® (butoconazole nitrate) vaginal cream, 2% is available in cartons containing one single-dose prefilled disposable applicator (NDC 64011-001-08).
Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). (See USP Controlled Room Temperature). Avoid heat above 30°C (86°F).
Manufactured for Ther-Rx Corporation by KV Pharmaceutical Co. St. Louis, MO 63044. 08/03. FDA Rev date: 7/24/2003This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 7/17/2008
Additional Gynazole Information
Gynazole - User Reviews
Gynazole User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.